Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05358717 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT05358717 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 159 participants.
The verdict
NCT05358717, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
Interventions
- DRUG Placebo
- DRUG PTC518
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05358717
The ClinicalTrials.gov registry entry for NCT05358717 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05358717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05358717 about?
NCT05358717 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)". The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
What is the current status of trial NCT05358717?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2022-06-03. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT05358717?
The interventions under investigation include: Placebo (DRUG), PTC518 (DRUG).
Who is sponsoring clinical trial NCT05358717?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.